A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (Evusheld™) for COVID-19 prophylaxis and treatment
D Focosi, A Casadevall - Viruses, 2022 - mdpi.com
Evusheld®(tixagevimab+ cilgavimab; AZD7442) was the first anti-Spike monoclonal
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …
antibody (mAb) cocktail designed not only for treatment but also with pre-exposure …
Tixagevimab/cilgavimab in SARS-CoV-2 prophylaxis and therapy: A comprehensive review of clinical experience
K Akinosoglou, EA Rigopoulos, G Kaiafa, S Daios… - Viruses, 2022 - mdpi.com
Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …
positive impact on controlling the spread of the pandemic, where they are available …
The prevention of COVID-19 in high-risk patients using tixagevimab–cilgavimab (Evusheld): Real-world experience at a large academic center
MM Al-Obaidi, AB Gungor, SE Kurtin… - The American journal of …, 2023 - Elsevier
Abstract Background Coronavirus disease 2019 (COVID-19) is associated with increased
morbidity and mortality among immunocompromised patients. Tixagevimab–cilgavimab (Tix …
morbidity and mortality among immunocompromised patients. Tixagevimab–cilgavimab (Tix …
Efficacy and safety of tixagevimab/cilgavimab to prevent COVID-19 (pre-exposure prophylaxis): a systematic review and meta-analysis
S Alhumaid, A Al Mutair, J Alali, N Al Dossary… - Diseases, 2022 - mdpi.com
Background: Tixagevimab/cilgavimab (TGM/CGM) are neutralizing monoclonal antibodies
(mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV …
(mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV …
[HTML][HTML] Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
The objective of this review was to examine the latest literature regarding the effectiveness
of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient …
of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient …
A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab …
I Benotmane, A Velay, GG Vargas… - Kidney …, 2022 - kidney-international.org
In this study, we show, for the first time, a significant decrease of the anti-RBD IgG 4 to 5
months after the administration of 150 mg of tixagevimab and 150 mg of cilgavimab. The …
months after the administration of 150 mg of tixagevimab and 150 mg of cilgavimab. The …
SARS-coV-2: an updated review highlighting its evolution and treatments
X Zhang, H Yuan, Z Yang, X Hu, YS Mahmmod, X Zhu… - Vaccines, 2022 - mdpi.com
Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide
have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The …
have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The …
Serum neutralization of SARS‐CoV‐2 Omicron BA. 2, BA. 2.75, BA. 2.76, BA. 5, BF. 7, BQ. 1.1 and XBB. 1.5 in individuals receiving Evusheld
Q Zhao, X Wang, Z Zhang, X Liu… - Journal of Medical …, 2023 - Wiley Online Library
The severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Omicron variant is
undergoing continuous evolution and convergent mutation. These new subvariants are …
undergoing continuous evolution and convergent mutation. These new subvariants are …
[HTML][HTML] Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan
M Ui, T Hirama, M Akiba, M Honda, T Kikuchi, Y Okada - Vaccine, 2023 - Elsevier
Abstract Background Lung transplant (LTx) recipients are at higher risk of infection with
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). There is an increasing …
severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). There is an increasing …
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
A Ustianowski - Expert Review of Anti-infective Therapy, 2022 - Taylor & Francis
Introduction There is a need to protect vulnerable individuals who do not respond to
vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …
vaccination against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) …